FORM 8-K

Current report filing

Filing Date: **2013-05-16** | Period of Report: **2013-05-16**
SEC Accession No. 0001019687-13-001935

FILER

ADVANCED CELL TECHNOLOGY, INC.
CIK:**1140098**| IRS No.: **870656515** | State of Incorp.:**DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-50295** | Film No.: **13849543**
SIC: **2834** Pharmaceutical preparations

Mailing Address
33 LOCKE DRIVE
MARLBOROUGH MA 01752

Business Address
33 LOCKE DRIVE
MARLBOROUGH MA 01752
508-756-1212

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **May 16, 2013**

ADVANCED CELL TECHNOLOGY, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware	**000-50295**	**87-0656515**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

33 Locke Drive, Marlborough, Massachusetts	**01752**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's Telephone Number, Including Area Code: **(508) 756-1212**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On May 16, 2013, Advanced Cell Technology, Inc. issued a press release confirming the results of one clinical trial participant in a clinical investigation of our retinal pigment epithelial (RPE) cells derived from human embryonic stem cells. The press release is furnished herewith as Exhibit 99.1.

The information furnished by this current report on Form 8-K, including Exhibit 99.1 hereto, should be considered in the context of our filings with the U.S. Securities and Exchange Commission ("SEC"), including our most recent annual report on Form 10-K and quarterly report on Form 10-Q (and the risk factors included in such Form 10-K and Form 10-Q), and other public disclosures that we have made and may make from time to time through filings with the SEC or by press release.

The information in this current report on Form 8-K, including Exhibit 99.1 hereto, is being furnished by the company and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and is not to be incorporated by reference into any registration statement or other filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as may be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Press Release Issued May 16, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Advanced Cell Technology, Inc.

By: /s/ Gary H. Rabin
Gary H. Rabin
Chief Executive Officer

Date: May 16, 2013

Advanced Cell Technology
33 Locke Drive • First Floor • Marlborough, MA 01752 • Tel 508.756.1212 • Fax 508.229.2333

ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment

MARLBOROUGH, Mass. – May 16, 2013 – Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today confirmed that the vision of a patient enrolled in a clinical investigation of the company's retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) has improved from 20/400 to 20/40 following treatment. The improvement was first reported on May 15, 2013, in a news article published by Reuters.

"We continue to be encouraged by the progress we see in our ongoing clinical investigations, though the results included in the article were confidential and not intended for publication at that time," commented Gary Rabin, chairman and CEO of ACT. "Our plan is still to publish additional results from the clinical investigations when we have a significant aggregation of data."

ACT is currently enrolling patients in three clinical trials in the U.S. and Europe for treatment of Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) with hESC-derived RPE cells. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the study's primary endpoint.

ACT cautions that the improvement in the patient's vision reported in this press release may not be indicative of future results of clinical trials of the RPE cells derived from hESCs. The information included in this press release should be considered in the context of ACT's filings with the U.S. Securities and Exchange Commission, including the risk factors included in our most recent annual report on Form 10-K and quarterly report on Form 10-Q.

About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements
Statements in this news release regarding plans for publishing additional results from ACT's clinical investigation, future prospects for our research and development programs, potential applications of our technology, opportunities for ACT and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in ACT's periodic reports, including ACT's report on Form 10-K for the year ended December 31, 2012 and ACT's report on Form 10-Q for the quarter ended March 31, 2013. Forward-looking statements are based on the beliefs, opinions and expectations of ACT's management at the time they are made, and ACT does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions and expectations of ACT's management at the time they are made, and ACT does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations or other circumstances should change. There can be no assurance that ACT's clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc., James Young, 212-732-4300

Press:
ACT Corporate Communications, Bill Douglass, 646-450-3615
or:
Russo Partners, David Schull, 858-717-2310